ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.717,26
0,35%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Virpax Pharmaceuticals Inc (VRPX)

  7. Virpax Pharmaceuticals Inc (VRPX) News

VRPX

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VRPX
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202413h30Business WireVirpax® Pharmaceuticals to Present at 2024 BIO International ConventionNASDAQ:VRPXVirpax Pharmaceuticals Inc
17/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
16/05/202422h00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VRPXVirpax Pharmaceuticals Inc
15/05/202414h00Business WireVirpax Announces Pricing of $2.25 Million Public OfferingNASDAQ:VRPXVirpax Pharmaceuticals Inc
15/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VRPXVirpax Pharmaceuticals Inc
13/05/202423h30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:VRPXVirpax Pharmaceuticals Inc
13/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
13/05/202422h10Business WireVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsNASDAQ:VRPXVirpax Pharmaceuticals Inc
13/05/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRPXVirpax Pharmaceuticals Inc
30/04/202413h30Business WireVirpax Announces Results of Maximum Tolerated Dose Study for Probudur™NASDAQ:VRPXVirpax Pharmaceuticals Inc
26/03/202412h30Business WireVirpax Pharmaceuticals Reports 2023 Year-End ResultsNASDAQ:VRPXVirpax Pharmaceuticals Inc
27/02/202413h31Business WireVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid PriceNASDAQ:VRPXVirpax Pharmaceuticals Inc
27/02/202413h30Business WireVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.NASDAQ:VRPXVirpax Pharmaceuticals Inc
07/02/202413h30Business WireVirpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical ResearchNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
31/01/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRPXVirpax Pharmaceuticals Inc
29/12/202313h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
29/12/202313h30Business WireVirpax Pharmaceuticals Announces Results of Special Shareholders MeetingNASDAQ:VRPXVirpax Pharmaceuticals Inc
13/12/202314h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
07/12/202315h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VRPXVirpax Pharmaceuticals Inc
07/12/202314h58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
07/12/202314h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRPXVirpax Pharmaceuticals Inc
21/11/202322h57Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VRPXVirpax Pharmaceuticals Inc
17/11/202313h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRPXVirpax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRPX

Kürzlich von Ihnen besucht

LSE
ZQ49
Citi Fun 24
TSXV
BLOC
ASX
DRG
EU
U351S
U351S
EU
BE0002836170
Fonds Regional Bruxelloi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten